A groundbreaking immunotherapy drug shows promising results in treating bowel cancer, potentially revolutionising traditional treatment methods. Pembrolizumab, known as Keytruda, targets a specific protein on immune cells, effectively eliminating cancer cells, according to The Guardian.In a recent clinical trial led by multiple esteemed institutions, including University College London and the Christie NHS Foundation Trust, patients with stage two or three bowel cancer and a specific genetic profile were given pembrolizumab before surgery instead of conventional chemotherapy.The Guardianreported that the results presented at the American Society of Clinical Oncology’s annual meeting are remarkable: 59% of patients showed no signs of cancer after treatment, with the remaining 41% seeing cancer removed during surgery. Importantly, all patients were declared cancer-free after the treatment, a stark improvement compared to standard chemotherapy outcomes.
